4 results match your criteria: "The Netherlands. s.e.ledevedec@lacdr.leidenuniv.nl.[Affiliation]"

Cell viability imaging in tumor spheroids DNA binding of a ruthenium(II) light-switch complex.

Chem Commun (Camb)

June 2024

Leiden Academic Center for Drug Research, Leiden University, P.O. Box 9502, 2300 RA Leiden, The Netherlands.

The famous ''light-switch'' ruthenium complex [Ru(bpy)(dppz)](PF) (1) has been long known for its DNA binding properties . However, the biological utility of this compound has been hampered by its poor cellular uptake in living cells. Here we report a bioimaging application of 1 as cell viability probe in both 2D cells monolayer and 3D multi-cellular tumor spheroids of various human cancer cell lines (U87, HepG2, A549).

View Article and Find Full Text PDF

FAIR High Content Screening in Bioimaging.

Sci Data

July 2023

Life Science Semantics, Leiden Institute of Advanced Computer Science, Leiden, The Netherlands.

The Minimum Information for High Content Screening Microscopy Experiments (MIHCSME) is a metadata model and reusable tabular template for sharing and integrating high content imaging data. It has been developed by combining the ISA (Investigations, Studies, Assays) metadata standard with a semantically enriched instantiation of REMBI (Recommended Metadata for Biological Images). The tabular template provides an easy-to-use practical implementation of REMBI, specifically for High Content Screening (HCS) data.

View Article and Find Full Text PDF

Differential response of luminal and basal breast cancer cells to acute and chronic hypoxia.

Breast Cancer Res Treat

April 2023

Division of Drug Discovery and Safety, Leiden Academic Centre of Drug Research, Leiden University, Leiden, The Netherlands.

Hypoxia is linked to disease progression and poor prognosis in several cancers, including breast cancer. Cancer cells can encounter acute, chronic, and/or intermittent periods of oxygen deprivation and it is poorly understood how the different breast cancer subtypes respond to such hypoxia regimes. Here, we assessed the response of representative cell lines for the luminal and basal A subtype to acute (24 h) and chronic hypoxia (5 days).

View Article and Find Full Text PDF

Acute vs. chronic vs. intermittent hypoxia in breast Cancer: a review on its application in in vitro research.

Mol Biol Rep

November 2022

Division of Drug Discovery and Safety, Leiden Academic Centre of Drug Research, Leiden University, Leiden, The Netherlands.

Article Synopsis
  • * Different types of hypoxia (acute, chronic, intermittent) affect tumor regions in varying ways, but there is no agreed-upon definition among scientists regarding their characteristics or impact on cancer cells.
  • * This review aims to clarify these definitions based on hypoxia exposure duration and oxygen levels and outlines methods for future research to improve understanding of hypoxia's role in breast cancer.
View Article and Find Full Text PDF